Literature DB >> 11313882

The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells.

G Bowers1, D Reardon, T Hewitt, P Dent, R B Mikkelsen, K Valerie, G Lammering, C Amir, R K Schmidt-Ullrich.   

Abstract

Activation of the epidermal growth receptor (ErbB1) occurs within minutes of a radiation exposure. Immediate downstream consequences of this activation are currently indistinguishable from those obtained with growth factors (GF), e.g. stimulation of the pro-proliferative mitogen-activated protein kinase (MAPK). To identify potential differences, the effects of GFs and radiation on other members of the ErbB family have been compared in mammary carcinoma cell lines differing in their ErbB expression profiles. Treatment of cells with EGF (ErbB1-specific) or heregulin (ErbB4-specific) resulted in a hierarchic transactivations of ErbB2 and ErbB3 dependent on GF binding specificity. In contrast, radiation indiscriminately activated all ErbB species with the activation profile reflecting that cell's ErbB expression profile. Downstream consequences of these ErbB interactions were examined with MAPK after specifically inhibiting ErbB1 (or 4) with tyrphostin AG1478 or ErbB2 with tyrphostin AG825. MAPK activation by GFs or radiation was completely inhibited by AG1478 indicating total dependance on ErbB1 (or 4) depending on which ErbB is expressed. Inhibiting ErbB2 caused an enhanced MAPK response simulating an amplified ErbB1 (or 4) response. Thus ErbB2 is a modulator of ErbB1 (or 4) function leading to different MAPK response profiles to GF or radiation exposure.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11313882     DOI: 10.1038/sj.onc.1204255

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  35 in total

Review 1.  Integrating radiotherapy with epidermal growth factor receptor antagonists and other molecular therapeutics for the treatment of head and neck cancer.

Authors:  Juliette Thariat; Luka Milas; K Kian Ang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-15       Impact factor: 7.038

Review 2.  Molecular therapy in head and neck oncology.

Authors:  Jacques Bernier; Søren M Bentzen; Jan B Vermorken
Journal:  Nat Rev Clin Oncol       Date:  2009-05       Impact factor: 66.675

3.  A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.

Authors:  Juergen M Schanzer; Katharina Wartha; Rebecca Croasdale; Samuel Moser; Klaus-Peter Künkele; Carola Ries; Werner Scheuer; Harald Duerr; Sandra Pompiati; Jan Pollman; Jan Stracke; Wilma Lau; Stefan Ries; Ulrich Brinkmann; Christian Klein; Pablo Umana
Journal:  J Biol Chem       Date:  2014-05-19       Impact factor: 5.157

4.  A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients.

Authors:  J J Raizer; P Giglio; J Hu; M Groves; R Merrell; C Conrad; S Phuphanich; V K Puduvalli; M Loghin; N Paleologos; Y Yuan; D Liu; A Rademaker; W K Yung; B Vaillant; J Rudnick; M Chamberlain; N Vick; S Grimm; I W Tremont-Lukats; J De Groot; K Aldape; M R Gilbert
Journal:  J Neurooncol       Date:  2016-01       Impact factor: 4.130

Review 5.  The counteradhesive proteins, thrombospondin 1 and SPARC/osteonectin, open the tyrosine phosphorylation-responsive paracellular pathway in pulmonary vascular endothelia.

Authors:  Anguo Liu; Deane F Mosher; Joanne E Murphy-Ullrich; Simeon E Goldblum
Journal:  Microvasc Res       Date:  2008-10-01       Impact factor: 3.514

Review 6.  HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.

Authors:  Jeffrey J Raizer
Journal:  J Neurooncol       Date:  2005-08       Impact factor: 4.130

7.  ErbB2, FoxM1 and 14-3-3ζ prime breast cancer cells for invasion in response to ionizing radiation.

Authors:  D M Kambach; V L Sodi; P I Lelkes; J Azizkhan-Clifford; M J Reginato
Journal:  Oncogene       Date:  2013-01-14       Impact factor: 9.867

8.  Epidermal growth factor receptor dependence of radiation-induced transcription factor activation in human breast carcinoma cells.

Authors:  George P Amorino; Virginia M Hamilton; Kristoffer Valerie; Paul Dent; Guido Lammering; Rupert K Schmidt-Ullrich
Journal:  Mol Biol Cell       Date:  2002-07       Impact factor: 4.138

9.  Molecular interactions of ErbB1 (EGFR) and integrin-β1 in astrocytoma frozen sections predict clinical outcome and correlate with Akt-mediated in vitro radioresistance.

Authors:  Miklós Petrás; Tamás Lajtos; Elza Friedländer; Almos Klekner; Eva Pintye; Burt G Feuerstein; János Szöllosi; György Vereb
Journal:  Neuro Oncol       Date:  2013-04-17       Impact factor: 12.300

10.  Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells.

Authors:  Hui-Fang Li; Jung-Sik Kim; Todd Waldman
Journal:  Radiat Oncol       Date:  2009-10-14       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.